Brief: Liminal Biosciences Provides Research And Development Update
02/06/2023 14:08
June 2 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES PROVIDES RESEARCH AND DEVELOPMENT
UPDATE
* LIMINAL BIOSCIENCES INC - GPR40 AGONIST DEVELOPMENT
PROGRAM ON
TRACK
* LIMINAL BIOSCIENCES INC-LMNL6326 NOMINATED AS LEAD
PRECLINICAL
CANDIDATE FOR OXER1 ANTAGONIST DEVELOPMENT PROGRAM
* LIMINAL BIOSCIENCES INC-ADVANCEMENT OF CTA ENABLING
PRECLINICAL
STUDIES OF LMNL6511 TO SUPPORT CTA FILING FOR PHASE 1 CLINICAL
TRIAL IN H2 2023
Source text for Eikon: ID:nCNW8Y1BQa
Further company coverage: LMNL.O
Recent news on Liminal BioSciences
See all newsBrief: Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Brief: Liminal Biosciences Files Amended Schedule 13E-3 And Supplement To Management Information Circular
Brief: Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
U.S. STOCKS ON THE MOVE-Liminal Biosciences, Tesla, Quad/Graphics
U.S. STOCKS ON THE MOVE-T2 Biosystems, GoodRx Holdings, ShiftPixy